Accelerate Precision Medicine Uptake With Impactful Scientific Engagement

As precision medicine continues to provide unique opportunities for patients, the management of the growing volume of information presents significant challenges for pharmaceutical companies when implementing effective programs.

The identification of biomarkers and engaging labs in the precision medicine journey is important. In this webinar, the expert speaker will demonstrate the effectiveness of impactful scientific engagement in enhancing the clinical utility of precision medicine.

With the expanding landscape of precision medicine, interpreting biomarker results is becoming increasingly pivotal. The key question now is: How can treating physicians be assisted in recognizing the clinical utility of this process?

By leveraging unique data sets, an extensive precision medicine network and experts from Diaceutics, pharmaceutical companies and treating physicians can get assistance in actioning therapeutics for appropriate patients. In this webinar, the attendees will gain insights into:

• How the nuances of biomarkers can be understood and managed
• How accurate prediction of opportunities and implementation of the most cost-effective interventions can remove barriers to maximize patient identification
• How labs are key stakeholders in the precision medicine process
• How labs and the local experts can be utilized to amplify precision medicine messaging
• How multidisciplinary involvement is more important than ever
• How well-informed and motivated lab partners are key to the success of any precision medicine asset

A multitude of stakeholders are involved in the precision medicine testing pathways, with the value of labs commonly being underestimated. It is a complicated process of scientific exchange combined with operational challenges and quality concerns.

Learn how the integration of proprietary data, broad Lab Network and unparalleled expertise in personal scientific lab engagement aid in devising strategies that activate optimal testing in the lab, the multidisciplinary team and even incorporate direct clinician engagement at pivotal moments—such as when biomarker-positive patients are identified—ensuring they receive the appropriate therapeutic options.

Register for this webinar today to discover how precision medicine programs can be optimized through strategic lab partnerships, actionable data and multidisciplinary collaboration.

Speaker

Ken Ruppel, Vice President of Scientific and Medical Services, Diaceutics

Ken Ruppel is the Vice President of Scientific and Medical Services at Diaceutics, where he plays a pivotal role in driving innovation and supporting global leaders in the development of impactful commercialization strategies for the launch of precision medicines. With over 25 years of experience in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets, Ken brings a wealth of expertise and strategic vision to Diaceutics.

Before joining Diaceutics, Ken served as the VP of Precision Medicine at Amplity Health, where he has supported the strategy and execution of 20+ companion diagnostic indications in the last six years. At Diaceutics, Ken leverages his extensive background to foster innovation and ensure that precision medicine strategies are effectively operationalized.

His commitment to advancing precision medicine is evident in his collaborative approach, working closely with pathologists and other key stakeholders to create academic-level care in the community.

Message Presenter